Cantor Fitzgerald Maintains Overweight on Janux Therapeutics, Lowers Price Target to $100
Benzinga Newsdesk 8 months ago
NewsPrice TargetAnalyst Ratings
Cantor Fitzgerald analyst Josh Schimmer maintains Janux Therapeutics (NASDAQ:JANX) with a Overweight and lowers the price target from $150 to $100.
Cantor Fitzgerald analyst Josh Schimmer maintains Janux Therapeutics (NASDAQ:JANX) with a Overweight and lowers the price target from $150 to $100.